Cargando…
Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
Hepatitis B reactivation (HBVr) in cancer patients is a well-established complication due to chemotherapy-induced immunosuppression. Studies have reported HBVr associated with immunosuppressive medications, such as rituximab, methotrexate, and high dose steroids. There are different risks for differ...
Autores principales: | Atteya, Asmaa, Ahmad, Aiman, Daghstani, Dima, Mushtaq, Kamran, Yassin, Mohamed A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480343/ https://www.ncbi.nlm.nih.gov/pubmed/33297765 http://dx.doi.org/10.1177/1073274820976594 |
Ejemplares similares
-
A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
por: Kaddoura, Rasha, et al.
Publicado: (2023) -
Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
por: Ismail, Mohamed A., et al.
Publicado: (2021) -
Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy
por: Petrushev, Bobe, et al.
Publicado: (2016) -
The effectiveness of tyrosine kinase inhibitor for chronic myeloid leukemia in tuberous sclerosis. A case report and review of literature
por: Al‐Abdulmalek, Abdulrahman, et al.
Publicado: (2023) -
High rate of hepatitis B reactivation during tyrosine kinase inhibitor treatment among patients with chronic myeloid leukemia in Korea
por: Kong, Jee Hyun, et al.
Publicado: (2022)